Clinical stage biopharmaceutical company Poxel SA (Euronext Paris:POXEL) announced on Monday that net sales of TWYMEEG in Japan surpassed JPY5bn in its Japanese partner Sumitomo Pharma Co Ltd's (TYO:4506) fiscal year 2024.
This achievement triggers a 10% royalty on all TWYMEEG net sales and a one-time JPY500m sales-based payment for Poxel.
These revenues will be used to repay the bond issue with OrbiMed and partially repay debt to IPF Partners.
Poxel expects escalating double-digit royalties and additional sales-based payments upon the achievement of future sales thresholds.
(USD1=JPY155.52)
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Moberg Pharma's MOB-015 fails to meet primary endpoint in phase 3 study
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine